Covington has advised OrbiMed. Goodwin Procter has advised Intellia Therapeutics. OrbiMed, a global healthcare investment firm, has entered into a non-dilutive senior secured term loan facility...
OrbiMed Provides $400 Million Non-Dilutive Debt Facility to Intellia Therapeutics
Curium to Acquire Lantheus in $8 Billion Merger
Kirkland & Ellis and Arnold & Porter Kaye Scholer LLP have advised Curium. Covington & Burling LLP and Ropes & Gray LLP have advised Lantheus. Curium...
Myriad Genetics Secures $200 Million Credit Facility
Covington has advised OrbiMed on the transaction. OrbiMed, a leading global healthcare investment firm, has provided a five-year senior secured term loan credit facility of up...
Oberland Capital’s $600 Million Investment in Biohaven
Covington & Burling advised Biohaven Ltd. on the transaction, and Cooley advised Oberland Capital. Biohaven Ltd. (NYSE: BHVN) announced it has entered into an agreement with...
Samsung’s $4.745 Billion CHIPS Act Award
Covington & Burling represented Samsung Electronics in the transaction. Samsung Electronics, one of the world’s largest chip manufacturers, received $4.745 billion in direct funding under the...
OrbiMed’s Financing Agreement with Poxel
OrbiMed was advised by LPA-CGR, BCLP, and Covington & Burling. Dechert LLP (Paris and New York) advised Poxel. OrbiMed announced it has entered into a non-dilutive...
Genezen’s Acquisition of Gene Therapy Manufacturing Facility
Covington & Burling represented uniQure in the transaction. uniQure N.V. (NASDAQ: QURE), a leading gene therapy company, announced the closing of the sale of its global...
OrbiMed’s $50 Million Financing
Covington & Burling represented OrbiMed Advisors, LLC in the transaction. OrbiMed Advisors, LLC, a healthcare investment firm, announced a debt financing facility for up to $50...
OrbiMed’s $125 Million Debt Financing
Covington & Burling advised OrbiMed on the deal. OrbiMed announced its $125 million debt financing with Verrica Pharmaceuticals, a dermatology therapeutics company developing medications for skin diseases...
DRI Healthcare Trust’s $85 Million of Royalty Interest in Breast Cancer Treatment
Covington advised Eisai in the transaction. Eisai Co., Ltd. signed its agreement to transfer all future economic rights for elacestrant (generic name), approved for the treatment for...
Caris Life Sciences’ $400 Million Secured Debt Financing
Covington advised OrbiMed on the deal. OrbiMed acted as the lead investor in a $400 million senior secured term loan facility provided to Caris Life Sciences, a...
Insmed Incorporated’s $775 Million Financing
Covington advised Insmed Incorporated on the deal while Fenwick represented Pharmakon. Walder Wyss advised the funds managed by Pharmakon Advisors, LP, BioPharma Credit and OrbiMed. Akin...